US 12,281,079 B2
Quinoline derivatives, processes for their preparation and uses thereof for the treatment of cancer
Raffaella Di Lucrezia, Wuppertal (DE); Tim Bergbrede, Dortmund (DE); Peter Nussbaumer, Dortmund (DE); and Peter Schröder, Dortmund (DE)
Assigned to Lead Discovery Center GmbH, Dortmund (DE)
Appl. No. 17/440,468
Filed by Lead Discovery Center GmbH, Dortmund (DE)
PCT Filed Mar. 19, 2020, PCT No. PCT/EP2020/057663
§ 371(c)(1), (2) Date Sep. 17, 2021,
PCT Pub. No. WO2020/188049, PCT Pub. Date Sep. 24, 2020.
Claims priority of application No. 19163976 (EP), filed on Mar. 20, 2019.
Prior Publication US 2022/0169616 A1, Jun. 2, 2022
Int. Cl. C07D 215/20 (2006.01); A61K 31/4375 (2006.01); A61K 31/438 (2006.01); A61K 31/4545 (2006.01); A61K 31/47 (2006.01); A61K 31/4709 (2006.01); A61K 31/496 (2006.01); A61K 31/5377 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); C07D 401/12 (2006.01); C07D 409/14 (2006.01); C07D 471/04 (2006.01); C07D 471/10 (2006.01); C07D 491/107 (2006.01); C07D 519/00 (2006.01)
CPC C07D 215/20 (2013.01) [A61K 31/4375 (2013.01); A61K 31/438 (2013.01); A61K 31/47 (2013.01); A61K 31/4709 (2013.01); A61K 31/5377 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07D 401/12 (2013.01); C07D 471/04 (2013.01); C07D 471/10 (2013.01); C07D 491/107 (2013.01); C07D 519/00 (2013.01)] 20 Claims
 
1. A compound of the general formula (I)

OG Complex Work Unit Chemistry
wherein
R is —H, or —C1-C4-alkyl;
R1 is —H, or -methyl;
M is CH or N;
V is —H, —OH, —Cl, —F, or —C1-C4-alkyl;
W is

OG Complex Work Unit Chemistry
R2 and R3 are identical or different and are
—H, —C1-C4-alkyl, halogen-C1-C4-alkyl, —C1-C4-alkoxy, —C1-C4-dialkylamino, —C2-C6-alkenyl, —C2-C6-alkynyl, -halogen, —CN or —CO—NH2;
X is -halogen, or —CN;
n=0, 1, or 2;
m=0 or 1;
Y is —NR4R5 wherein
R4 is —H, or —C1-C4-alkyl, and
R5 is —H, —C1-C4-alkyl, an unsubstituted or substituted —C3-C6-cycloalkyl; or
an unsubstituted or substituted pyridine residue; or
an unsubstituted or substituted phenyl residue; or
Y is —NR4R5 wherein N, R4 and R5 form an unsubstituted or substituted 4-, 5- or 6-membered saturated heterocycle; or
Y is —OR6, wherein R6 is —H or —C1-C4-alkyl;
or a pharmaceutically or veterinary acceptable salt, hydrate or solvate thereof.